This article is thought provoking in many ways and has made me...

This article is thought provoking in many ways and has made me do further research into the innovative WH space. The article was published in Fortune in April 2023 and its key message was that innovative WH contraception is not being made available to women because of poor insurance coverage (the article asserts that up to 50% of the insurance claims for these products which include Annovera and Nextstellis are rejected by PBM and insurers) and the smaller one product companies like Evofem (makes Phexxi a contaceptive vaginal gel), Agile (makes Twirler a low estrogen contraceptive patch) are going broke.

Since the article was written, Evofem was sold to Aditxt in December for US$100M with the purchaser assuming the debt of the company, Agile is on the brink of bankruptcy and making strong representations to Congress for strengthening compliance to the ACA (Affordable Care Act).
https://www.biospace.com/article/releases/agile-therapeutics-provides-update-on-actions-being-taken-to-strengthen-the-affordable-care-act-s-no-cost-contraceptive-coverage-requirement/?s=92

An improvement in compliance to the ACA will have huge positive effects for MYX and our CEO has made this comment recently again but the wheels of government move slowly and it may not be quick enough to save Agile but may present opportunities for companies which are cashed up.

You're right Stephencca , MYX is now making profits on its WH investment and we're not in the same boat as one product companies (thanks to THMD). In summary, improving ACA compliance has huge implications for MYX and judicial further purchases in this space going forward will produce a very, very profitable company.